UY26970A1 - Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivos - Google Patents
Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivosInfo
- Publication number
- UY26970A1 UY26970A1 UY26970A UY26970A UY26970A1 UY 26970 A1 UY26970 A1 UY 26970A1 UY 26970 A UY26970 A UY 26970A UY 26970 A UY26970 A UY 26970A UY 26970 A1 UY26970 A1 UY 26970A1
- Authority
- UY
- Uruguay
- Prior art keywords
- treatment
- acetilcolinesterase
- gaba
- agonists
- inhibitors
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 abstract 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24114500P | 2000-10-17 | 2000-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY26970A1 true UY26970A1 (es) | 2002-06-20 |
Family
ID=22909428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY26970A UY26970A1 (es) | 2000-10-17 | 2001-10-16 | Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20020151591A1 (enExample) |
| EP (1) | EP1328294A2 (enExample) |
| JP (1) | JP2004511512A (enExample) |
| KR (1) | KR20030046509A (enExample) |
| AR (1) | AR030893A1 (enExample) |
| AU (2) | AU9411701A (enExample) |
| CA (1) | CA2426120A1 (enExample) |
| HU (1) | HUP0302476A3 (enExample) |
| IL (1) | IL155225A0 (enExample) |
| NZ (1) | NZ525103A (enExample) |
| PE (1) | PE20020473A1 (enExample) |
| UY (1) | UY26970A1 (enExample) |
| WO (1) | WO2002032412A2 (enExample) |
| ZA (1) | ZA200302918B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10119862A1 (de) * | 2001-04-24 | 2002-11-07 | Hf Arzneimittelforsch Gmbh | Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen |
| JP2006512417A (ja) * | 2002-12-24 | 2006-04-13 | ニューロケム （インターナショナル） リミテッド | β−アミロイド関連疾患の治療のための治療用製剤 |
| US8299062B2 (en) * | 2003-09-17 | 2012-10-30 | Franklin Volvovitz | Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction |
| EP1666066A4 (en) * | 2003-09-19 | 2007-03-28 | Eisai R&D Man Co Ltd | DRUG AGAINST THE DOWN SYNDROME |
| TW200533371A (en) * | 2004-04-15 | 2005-10-16 | Dainippon Pharmaceutical Co | Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative |
| US20050267076A1 (en) * | 2004-05-14 | 2005-12-01 | Johns Hopkins University | Method for improving cognitive function |
| CA2576258A1 (en) * | 2004-08-09 | 2006-02-16 | Warner-Lambert Company Llc | Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
| CN100382802C (zh) * | 2005-08-08 | 2008-04-23 | 赵德禄 | 治疗自主神经系统功能紊乱的药物 |
| CA2686155C (en) * | 2006-05-22 | 2016-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Pharmacological treatment of cognitive impairment |
| CA2666219C (en) | 2006-10-16 | 2017-02-07 | Bionomics Limited | Novel anxiolytic compounds |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| EP2091948B1 (en) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
| EA037187B1 (ru) | 2010-02-09 | 2021-02-17 | Дзе Джонс Хопкинс Юниверсити | Способ и композиция для лечения когнитивного расстройства |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| CA2789440C (en) | 2010-03-10 | 2020-03-24 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| BR112013012062B1 (pt) | 2010-11-15 | 2020-06-02 | Agenebio, Inc | Composto derivado da piridazina ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso do composto |
| US9023848B2 (en) | 2011-03-02 | 2015-05-05 | Bionomics Limited | Small-molecules as therapeutics |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| CN103649086A (zh) | 2011-05-12 | 2014-03-19 | 生态学有限公司 | 制备萘啶的方法 |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| JP6433482B2 (ja) | 2013-03-15 | 2018-12-05 | エージンバイオ， インコーポレイテッド | 認知機能を改善するための方法および組成物 |
| US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| NZ722077A (en) | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| AU2016268096B2 (en) | 2015-05-22 | 2021-04-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| CN108026107B (zh) | 2015-06-19 | 2021-07-30 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| IL279530B1 (en) | 2018-06-19 | 2025-09-01 | Agenebio Inc | Benzodiazepine history, preparations, and methods for treating cognitive disorder |
| AU2023324882A1 (en) | 2022-08-19 | 2025-03-20 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4374138A (en) * | 1981-11-13 | 1983-02-15 | Warner-Lambert Company | Antibacterial amide compounds, compositions, and methods of use |
| US5870723A (en) * | 1994-11-28 | 1999-02-09 | Pare, Jr.; David Ferrin | Tokenless biometric transaction authorization method and system |
| US6088683A (en) * | 1996-08-21 | 2000-07-11 | Jalili; Reza | Secure purchase transaction method using telephone number |
| US6016476A (en) * | 1997-08-11 | 2000-01-18 | International Business Machines Corporation | Portable information and transaction processing system and method utilizing biometric authorization and digital certificate security |
| US6143760A (en) * | 1997-08-25 | 2000-11-07 | Neurogen Corporation | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands |
| YU10500A (sh) * | 1997-08-25 | 2002-10-18 | Neurogen Corporation | Supstituisani 4-okso-naptiridin-3-karboksamidi kao gaba moždani receptorski liganidi |
| GB9805561D0 (en) * | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
-
2001
- 2001-10-12 US US09/976,347 patent/US20020151591A1/en not_active Abandoned
- 2001-10-15 IL IL15522501A patent/IL155225A0/xx unknown
- 2001-10-15 EP EP01974604A patent/EP1328294A2/en not_active Withdrawn
- 2001-10-15 AU AU9411701A patent/AU9411701A/xx active Pending
- 2001-10-15 HU HU0302476A patent/HUP0302476A3/hu unknown
- 2001-10-15 AU AU2001294117A patent/AU2001294117B2/en not_active Ceased
- 2001-10-15 NZ NZ52510301A patent/NZ525103A/xx unknown
- 2001-10-15 AR ARP010104836A patent/AR030893A1/es unknown
- 2001-10-15 CA CA002426120A patent/CA2426120A1/en not_active Abandoned
- 2001-10-15 WO PCT/IB2001/001934 patent/WO2002032412A2/en not_active Ceased
- 2001-10-15 KR KR10-2003-7005292A patent/KR20030046509A/ko not_active Ceased
- 2001-10-15 JP JP2002535650A patent/JP2004511512A/ja active Pending
- 2001-10-16 PE PE2001001026A patent/PE20020473A1/es not_active Application Discontinuation
- 2001-10-16 UY UY26970A patent/UY26970A1/es not_active Application Discontinuation
-
2003
- 2003-04-11 ZA ZA200302918A patent/ZA200302918B/en unknown
-
2004
- 2004-08-06 US US10/912,993 patent/US20050009861A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002032412A3 (en) | 2003-03-20 |
| HUP0302476A3 (en) | 2005-05-30 |
| EP1328294A2 (en) | 2003-07-23 |
| AR030893A1 (es) | 2003-09-03 |
| JP2004511512A (ja) | 2004-04-15 |
| PE20020473A1 (es) | 2002-06-14 |
| US20050009861A1 (en) | 2005-01-13 |
| HUP0302476A2 (hu) | 2003-11-28 |
| IL155225A0 (en) | 2003-11-23 |
| US20020151591A1 (en) | 2002-10-17 |
| CA2426120A1 (en) | 2002-04-25 |
| WO2002032412A2 (en) | 2002-04-25 |
| AU9411701A (en) | 2002-04-29 |
| KR20030046509A (ko) | 2003-06-12 |
| ZA200302918B (en) | 2004-04-13 |
| AU2001294117B2 (en) | 2006-07-27 |
| NZ525103A (en) | 2004-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY26970A1 (es) | Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivos | |
| ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
| NO20024221D0 (no) | Blandinger inneholdende alfa-2-adrenerge agonistkomponenter | |
| ECSP034492A (es) | Derivados de hidroxamato utiles como inhibidores de desacetilasa | |
| ES2421948T3 (es) | Compuestos y composiciones para suministrar agentes activos | |
| PA8557401A1 (es) | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares | |
| ATE420879T1 (de) | Indolizine als kinaseproteinhemmer | |
| CR9244A (es) | AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA | |
| AR026173A1 (es) | Inhibidores de neuraminidasas. | |
| ECSP034750A (es) | Derivados de espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7 | |
| UY26092A1 (es) | Uso de inhibidores de cyp2d6 en terapias de combinacion | |
| ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
| ATE512151T1 (de) | Pyrrolotriazin-kinaseinhibitoren | |
| EA200501928A1 (ru) | Пирролодигидроизохинолины как ингибиторы pde10 | |
| UY29479A1 (es) | Inhibidores de adn-pk | |
| CR7332A (es) | INHIBIDORES DEL FACTOR Xa Y DE OTRAS PROTEASAS DE SERINA IMPLICADAS EN LA CASCADA DE LA COAGULACION | |
| DK1948155T3 (da) | Farmaceutiske præparater omfattende droxidopa | |
| ECSP077426A (es) | USO DE UN INHIBIDOR DE mTOR EN EL TRATAMIENTO DE LEIOMIOMA UTERINO | |
| BR0307017A (pt) | agentes hipnóticos sedativos de ação rápida para anestesia e sedação | |
| ECSP088743A (es) | Anticuerpos para egfl7 y métodos para su uso | |
| HN2002000110A (es) | Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple. | |
| UY27203A1 (es) | Bencimidazoles útiles en el tratamiento de la disfunción sexual | |
| DE60323496D1 (de) | Reinigungsmittel für harte oberflächen | |
| ECSP034598A (es) | Compuesto lactamico | |
| PA8582201A1 (es) | Indoles 2,7-sustituidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20150429 |